3 news items
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
RLYB
9 May 24
Innovation – JJDC, Inc.
In February 2024
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
JNJ
RLYB
11 Apr 24
, Rallybio received an equity investment of $6.6 million from Johnson & Johnson Innovation.
Rallybio is developing RLYB212, a human
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
RLYB
10 Apr 24
). In addition, Rallybio received an equity investment of $6.6 million from Johnson & Johnson Innovation – JJDC, Inc
- Prev
- 1
- Next